Author:
Sowunmi Akin,Akano Kazeem,Ntadom Godwin,Ayede Adejumoke,Oguche Stephen,Agomo Chimere,Okafor Henrietta,Watila Ismaila,Meremikwu Martin,Ogala William,Agomo Philip,Adowoye Elsie,Fatunmbi Bayo,Aderoyeje Temitope,Happi Christian,Gbotosho Grace,Folarin Onikepe
Abstract
Background: In severe malaria, intravenous artesunate may cause delayed haemolytic anaemia but there has been little evaluation of the propensity of oral artemisinin-based combination treatments (ACTs) to cause late-appearing anaemia. Methods: The frequency of anaemia (haematocrit <30%), and temporal changes in haematocrit were evaluated in 1,191 malarious children following ACTs. “Haematocrit conservation” was evaluated by using the fall in haematocrit/1,000 asexual parasites cleared from the peripheral blood (FIH/1,000 asexual parasites cpb), and the ratio of the average haematocrit (on the first 3 days of starting treatment):total parasitaemia cleared. Results: The frequency of anaemia decreased significantly following treatment. FIH/1,000 asexual parasites cpb, average haematocrit:total parasitaemia cleared, and mean haematocrit 5 weeks after treatment began were significantly lower in hyperparasitaemic children than in children without hyperparasitaemia, suggesting haematocrit conservation during treatment followed later by a loss of haematocrit. Asymptomatic late-appearing anaemia occurred in 6% of the children. Conclusion: Artesunate-amodiaquine and artemether-lumefantrine contribute to haematocrit conservation at high parasitaemias but may cause late-appearing anaemia.
Subject
Infectious Diseases,Pharmacology (medical),Drug Discovery,Pharmacology,Oncology,General Medicine
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献